EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Writing the Wrong Phosphorylation Code: Pathogenic Variants Reveal Disease‐Relevant CK2 Signaling Nodes

Luca Cesaro, Valentina Bosello Travain, Maria Ruzzene, Mauro Salvi

Journal of Cellular Physiology · 2026-11 · 241 (11)

DOI: 10.1002/jcp.70255 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Protein kinase CK2 is a ubiquitous and constitutively active serine/threonine kinase linked to more than 600 phosphorylation sites in humans. Although many CK2‐dependent events have been characterized in vitro or associated with cellular phenotypes, whether their effects persist in vivo, where tissue context, compensatory mechanisms, and signaling‐network adaptation can reshape signaling output, often remains unclear. In this Review, we discuss pathogenic human variation as a means of prioritizing disease‐relevant CK2 phosphorylation events, focusing on variants that replace phosphoacceptor residues or alter sequence determinants required for CK2 recognition and may therefore lead to loss of phosphorylation‐dependent regulation. We first examine established examples in which disease‐associated variants affect functionally well‐characterized CK2 sites or their recognition determinants and then consider putative sites for which CK2‐dependent phosphorylation and its contribution to pathogenicity remain hypothetical. By considering evidence for cellular phosphorylation, functional effects, and relevance to disease pathogenesis, this genetics‐guided framework can help categorize regulatory events according to the strength of the evidence and prioritize further study within the broad CK2 phosphoproteome.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →